As host of the BIO Buzz Center during the 2017 BIO CEO & Investor Conference in New York City, Life Science Leader magazine conducted five video interviews with a number of industry executives and thought leaders. Jeff Marrazzo is the co-founder and CEO of Spark Therapeutics (NASDAQ: ONCE). Marrazzo led the creation and growth of Spark Therapeutics from a research center within the Children’s Hospital of Philadelphia (CHOP) to a fully integrated gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now. Under his leadership, Spark has successfully completed the first randomized, controlled Phase 3 trial of an investigative gene therapy for a genetic disease and established human proof-of-concept of Spark’s gene therapy platform in both the retina and the liver. The company is currently preparing the first Biologics License Application (BLA) submission for a gene therapy for a genetic disease in the U.S. Since being featured in Life Science Leader magazine’s May 2104 issue (p. 46 – 49), the company has grown to a market cap of over $2 billion. Below is my short video interview with Jeff Marrazzo, co-founder and CEO of Spark Therapeutics.